JEK Trust tied to CEO sells 180,000 Alignment Healthcare (ALHC) shares

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Alignment Healthcare reported that JEK Trust, of which Chief Executive Officer and director John E. Kao is trustee, sold 180,000 shares of the company’s common stock on 02/10/2026 at a weighted-average price of $20.4853 per share under a Rule 10b5-1 trading plan adopted on 03/12/2025.

After this sale, 2,652,641 shares are held indirectly through JEK Trust and 1,568,379 shares are held directly. The sale price reflects multiple trades in a range from $20.23 to $20.66 per share.

Insider Trade Summary

Net Seller: 180,000 shares ($3,687,354)

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 180,000 shs ($3.69M)

Type	Security	Shares	Price	Value
Sale	Common Stock	180,000	$20.4853	$3.69M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,652,641 shares (Indirect, See Footnote); Common Stock — 1,568,379 shares (Direct)

Footnotes (1)

Date of adoption of Rule 10b5-1 plan: 03/12/2025 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.23 to $20.66. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Form 4 Insider Transactions: What Each Field Means →

02/10/2026 - 09:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last)

(First)

(Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE

92868

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/10/2026		S⁽¹⁾		180,000	D	$20.4853⁽²⁾	2,652,641	I	See Footnote⁽³⁾
Common Stock								1,568,379	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Date of adoption of Rule 10b5-1 plan: 03/12/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.23 to $20.66. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Alignment Healthcare (ALHC) disclose in this Form 4?

Alignment Healthcare disclosed that JEK Trust, associated with CEO John E. Kao, sold 180,000 shares of common stock on 02/10/2026. The transaction was reported as a sale at a weighted-average price of $20.4853 per share, executed in multiple trades within a disclosed price range.

At what price were the Alignment Healthcare (ALHC) shares sold in the reported transaction?

The 180,000 Alignment Healthcare shares were sold at a weighted-average price of $20.4853 per share. Individual trades occurred in a range from $20.23 to $20.66 per share, with the reporting person offering to provide detailed breakdowns of share counts at each specific price upon request.

Who executed the reported sale of Alignment Healthcare (ALHC) shares?

The reported sale represents securities held by JEK Trust, dated February 8, 2021, of which John E. Kao is the trustee. Kao is Alignment Healthcare’s Chief Executive Officer and a director, and the transaction is reported as indirect ownership through this trust structure.

How many Alignment Healthcare (ALHC) shares does John E. Kao hold after the transaction?

Following the transaction, 2,652,641 Alignment Healthcare shares are held indirectly through JEK Trust, and 1,568,379 shares are held directly. These figures show Kao’s reported beneficial ownership positions immediately after the 180,000-share sale completed on 02/10/2026, divided between indirect and direct holdings.

Was the Alignment Healthcare (ALHC) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the sale was executed under a Rule 10b5-1 trading plan adopted on 03/12/2025. Such plans allow prearranged trading of shares according to preset instructions, providing a structured framework for insider transactions over time once established.

What additional disclosure did the Alignment Healthcare (ALHC) insider provide about trade pricing?

The insider disclosed that the reported price is a weighted-average from multiple trades between $20.23 and $20.66 per share. The reporting person committed to supply full details on the number of shares sold at each individual price to the company, shareholders, or regulators upon request.